These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34931414)

  • 1. Efficacy and safety of guselkumab in two psoriatic patients with hepatitis B and C virus infection.
    Messina F; Peccerillo F; Odorici G; Conti A; Piaserico S
    Dermatol Ther; 2022 Mar; 35(3):e15281. PubMed ID: 34931414
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety profile of guselkumab in treatment of patients with psoriasis and coexisting hepatitis B or C: A multicenter prospective cohort study.
    Huang YH; Yen JS; Li SH; Chiu HY
    J Am Acad Dermatol; 2024 May; 90(5):1083-1086. PubMed ID: 38307145
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment on: 'Paradoxical psoriatic arthritis in a patient with psoriasis treated with guselkumab'.
    Akturk S; Altunisik N; Buyukavci R; Turkmen D
    Clin Exp Dermatol; 2022 Jul; 47(7):1363-1364. PubMed ID: 35266569
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab.
    Megna M; Marano L; Camela E; Potestio L; Fabbrocini G; Scalvenzi M; Guerrasio G
    Dermatol Ther; 2022 Oct; 35(10):e15766. PubMed ID: 35959513
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Deodhar A; Gottlieb AB; Boehncke WH; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC;
    Lancet; 2018 Jun; 391(10136):2213-2224. PubMed ID: 29893222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
    Mease PJ; Rahman P; Gottlieb AB; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; van der Heijde D; McInnes IB;
    Lancet; 2020 Apr; 395(10230):1126-1136. PubMed ID: 32178766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical psoriatic arthritis in a patient with psoriasis treated with guselkumab.
    Carriero A; Lubrano E; Picerno V; Padula AA; D'Angelo S
    Clin Exp Dermatol; 2022 Apr; 47(4):783-785. PubMed ID: 34905263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
    Deodhar A; Helliwell PS; Boehncke WH; Kollmeier AP; Hsia EC; Subramanian RA; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; Ritchlin CT;
    Lancet; 2020 Apr; 395(10230):1115-1125. PubMed ID: 32178765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.
    Rahman P; Ritchlin CT; Helliwell PS; Boehncke WH; Mease PJ; Gottlieb AB; Kafka S; Kollmeier AP; Hsia EC; Xu XL; Shawi M; Sheng S; Agarwal P; Zhou B; Ramachandran P; Zhuang Y; McInnes IB
    J Rheumatol; 2021 Dec; 48(12):1815-1823. PubMed ID: 33934076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.
    Boehncke WH; Brembilla NC; Nissen MJ
    Expert Rev Clin Immunol; 2021 Jan; 17(1):5-13. PubMed ID: 33251833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
    Reich K; Griffiths CEM; Gordon KB; Papp KA; Song M; Randazzo B; Li S; Shen YK; Han C; Kimball AB; Armstrong AW; Foley P; Blauvelt A
    J Am Acad Dermatol; 2020 Apr; 82(4):936-945. PubMed ID: 31809827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
    Reich K; Armstrong AW; Foley P; Song M; Miller M; Shen YK; You Y; Han C; Gordon KB
    Am J Clin Dermatol; 2020 Dec; 21(6):881-890. PubMed ID: 32910434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life experience of guselkumab in patients with psoriasis.
    Snast I; Sherman S; Holzman R; Hodak E; Pavlovsky L
    Dermatol Ther; 2020 Nov; 33(6):e13964. PubMed ID: 32618384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.
    Puig L
    Expert Rev Clin Immunol; 2019 Jun; 15(6):589-597. PubMed ID: 30920855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
    Reich K; Papp KA; Armstrong AW; Wasfi Y; Li S; Shen YK; Randazzo B; Song M; Kimball AB
    Br J Dermatol; 2019 May; 180(5):1039-1049. PubMed ID: 30485400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab for psoriatic arthritis.
    Cuchacovich RS; Espinoza LR
    Lancet; 2009 Feb; 373(9664):605-6. PubMed ID: 19217153
    [No Abstract]   [Full Text] [Related]  

  • 17. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.
    Helliwell PS; Deodhar A; Gottlieb AB; Boehncke WH; Xu XL; Xu S; Wang Y; Hsia EC; Gladman DD; Ritchlin CT
    Arthritis Care Res (Hoboken); 2020 Nov; 72(11):1579-1588. PubMed ID: 31421033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
    Blauvelt A; Thaçi D; Papp KA; Ho V; Ghoreschi K; Kim BS; Miller M; Shen YK; You Y; Chan D; Yu J; Yang YW; Lebwohl MG; Gottlieb AB; Crowley J; Foley P
    Br J Dermatol; 2023 Jul; 189(1):132-134. PubMed ID: 36944555
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
    Coates LC; Gossec L; Theander E; Bergmans P; Neuhold M; Karyekar CS; Shawi M; Noël W; Schett G; McInnes IB
    Ann Rheum Dis; 2022 Mar; 81(3):359-369. PubMed ID: 34819273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of Chronic HCV Infection Reactivation in a Psoriasis Patient Treated with Guselkumab.
    Megna M; Fabbrocini G; Gallo L; Patrì A; Ruggiero A
    Curr Drug Saf; 2022; 17(4):390-392. PubMed ID: 35255793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.